Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points.
Although chronic infections with viruses such as HIV and hepatitis C virus have been associated with regulatory T cell (Treg)-mediated suppression of virus-specific CD8(+) T-cell activity, no causal relationship between Tregs and chronic viral set points has been established. Using transgenic mice in which Tregs can be selectively ablated, we now show that transient depletion of Tregs during a chronic retroviral infection allows exhausted CD8(+) T cells to regain antiviral functions, including secretion of cytokines, production of cytotoxic molecules, and virus-specific cytolytic activity. Furthermore, short-term Treg ablation resulted in long-term reductions in chronic virus loads. These results demonstrate that Treg-mediated immunosuppression can be a significant factor in the maintenance of chronic viral infections and that Treg-targeted immunotherapy could be a valuable component in therapeutic strategies to treat chronic infectious diseases.
Institute for Virology, University Clinics Essen, University of Duisburg-Essen, 45122 Essen, Germany.
Kirsten K
KK
Dietze
Gennadiy
G
Zelinskyy
Kathrin
K
Gibbert
Simone
S
Schimmer
Sandra
S
Francois
Lara
L
Myers
Tim
T
Sparwasser
Kim J
KJ
Hasenkrug
Ulf
U
Dittmer
D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002908:Chronic Disease; D016207:Cytokines / Q000276:immunology; D008212:Lymphocyte Depletion; D051379:Mice; D008822:Mice, Transgenic; D012192:Retroviridae Infections / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory
D016207:Cytokines
J Immunol. 2006 Mar 15;176(6):3342-9
16517701
J Virol. 2005 Nov;79(21):13239-49
16227247
J Immunol. 2003 Jul 1;171(1):27-31
12816979
J Infect Dis. 1999 Apr;179(4):859-70
10068581
Blood. 2006 Dec 1;108(12):3808-17
16902147
Science. 1996 May 24;272(5265):1167-70
8638160
Virology. 1973 Oct;55(2):363-70
4742777
Nat Immunol. 2002 Feb;3(2):135-42
11812990
Nat Immunol. 2005 Apr;6(4):353-60
15785761
J Immunol. 2002 Sep 15;169(6):3191-9
12218137
J Immunol. 2007 Dec 15;179(12):8059-68
18056346
Eur J Immunol. 2006 Oct;36(10):2658-70
16981182
J Virol. 1998 Aug;72(8):6559-64
9658100
Nat Med. 2006 Dec;12(12):1365-71
17115046
Nature. 2006 Feb 9;439(7077):682-7
16382236
J Virol. 1996 Nov;70(11):7773-82
8892898
J Immunol. 2005 Apr 1;174(7):4407-14
15778406
J Immunol. 2005 Mar 15;174(6):3143-7
15749840
Immunity. 2008 Dec 19;29(6):1009-21
19062316
Nat Immunol. 2009 Jan;10(1):29-37
19043418
J Immunol. 2004 Apr 15;172(8):4686-90
15067043
Nat Immunol. 2010 Dec;11(12):1093-101
20953201
Nat Immunol. 2005 Apr;6(4):345-52
15785760
J Exp Med. 2007 Jan 22;204(1):57-63
17200412
J Clin Invest. 2005 Dec;115(12):3623-33
16308572
J Exp Med. 2004 Aug 2;200(3):331-43
15280419
J Immunol. 2009 Aug 1;183(3):1636-43
19587016
PLoS Pathog. 2009 Aug;5(8):e1000406
19714239
J Immunol Methods. 2003 Oct 1;281(1-2):65-78
14580882
Nat Med. 2003 Nov;9(11):1377-82
14528297
Immunity. 2004 Mar;20(3):293-303
15030773
J Virol. 2007 Nov;81(21):11881-90
17728236
Nature. 2006 Sep 21;443(7109):350-4
16921384
J Virol. 2005 Aug;79(16):10619-26
16051854
Blood. 2009 Oct 8;114(15):3199-207
19671923
J Virol. 2008 Jan;82(1):408-18
17959678
J Virol. 2004 Mar;78(5):2454-9
14963140
J Virol. 1998 Aug;72(8):6554-8
9658099
Immunity. 2008 Nov 14;29(5):782-94
19006695
J Immunol. 2010 May 1;184(9):4696-707
20351188
J Virol. 2008 Jan;82(1):21-30
17855537
J Immunol. 2009 Dec 15;183(12):7631-4
19923467
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9226-30
11459933
Blood. 2006 Jun 15;107(12):4781-9
16467198
FEBS Lett. 1997 May 5;407(3):313-9
9175875